Sagimet Biosciences (SGMT) Payables (2022 - 2026)

Sagimet Biosciences' Payables history runs 5 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Payables fell 28.54% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (down 28.54% YoY), while the FY2025 annual figure was $1.3 million, down 8.14% from the prior year.
• Payables was $2.3 million for Q1 2026 at Sagimet Biosciences, up from $1.3 million in the prior quarter.
• In the past five years, Payables ranged from a high of $4.2 million in Q3 2025 to a low of $186000.0 in Q4 2023.
• Historically, Payables has averaged $1.8 million across 5 years, with a median of $1.7 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Payables tumbled 83.47% in 2023, then surged 666.13% in 2024.
• A 5-year view of Payables shows it stood at $1.1 million in 2022, then sank by 83.47% to $186000.0 in 2023, then soared by 666.13% to $1.4 million in 2024, then slipped by 8.14% to $1.3 million in 2025, then soared by 75.94% to $2.3 million in 2026.
• The last three Payables figures came in at $2.3 million (Q1 2026), $1.3 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.